Why the pathology report is the starting point
Non-small cell lung cancer is not one disease. The pathology report tells the treating team what was actually seen under the microscope: whether the sample is adenocarcinoma, squamous cell carcinoma, large cell carcinoma or another subtype, and whether the tissue came from a lung biopsy, a lymph node, a pleural fluid sample or a surgical resection. That distinction matters because different subtypes behave differently and are not treated identically.
The report should also state how the sample was obtained and whether the material was adequate for testing. A small needle biopsy may provide enough tissue for diagnosis but not enough for every molecular test. If the report says the sample was limited or suboptimal, the treating team may need to discuss whether further sampling is possible or whether a blood-based test is appropriate. That is a clinical decision, not something to assume from the report alone.
For a patient planning care in China, the practical question is whether the original pathology slides and blocks can be made available. Many hospitals will want to review the actual tissue rather than rely only on a typed report. Ask your current hospital what it can release and in what format. Do not assume that a scanned report is sufficient for every purpose; ask the receiving team what it requires.
What a biomarker report adds, and what it does not
Biomarker testing looks for specific molecular features in the tumour tissue. In non-small cell lung cancer, common targets include EGFR mutations, ALK rearrangements, ROS1 rearrangements, BRAF mutations, KRAS mutations, MET alterations, RET rearrangements, NTRK fusions and HER2 alterations. A report may also include PD-L1 expression, which is measured differently and is not a mutation.
A positive biomarker result does not automatically mean a particular drug is right for you. It means the treating team has one more piece of information to weigh alongside stage, histology, prior treatment, general health and your own priorities. A negative result does not mean no treatment is available. It means that specific marker was not found, and other options may still be relevant.
The report should state which tests were performed, which method was used, and whether the result is positive, negative or indeterminate. If a test was not performed, the report may not say so explicitly. Ask which markers were tested and which were not. If the treating team needs a marker that was not tested, they will decide whether the existing tissue can be used for additional testing or whether new sampling is needed.
Previous cancer therapy changes how reports are read
If you have already received treatment, the treating team needs to know what you received, when, and how the cancer responded. That history changes how the pathology and biomarker reports are interpreted. A biomarker result from a sample taken before treatment may not reflect the cancer after treatment. In some situations, a new biopsy may be considered to reassess the disease.
Bring a clear summary of prior therapy: surgery, radiation, chemotherapy, targeted therapy, immunotherapy or clinical trial participation. Include dates and the reason each treatment stopped. If you do not have this in writing, ask your treating hospital for a treatment summary. The receiving team will want to understand not only what was given but also what happened next.
Do not assume that a prior treatment rules out a future option. Equally, do not assume that a treatment used elsewhere will be available or suitable in China. The treating team must assess this against your current reports and their own protocols. Ask them directly what they need to make that assessment.
Local and systemic options: what the reports help clarify
For non-small cell lung cancer, treatment discussions often involve local options such as surgery or radiation, and systemic options such as chemotherapy, targeted therapy or immunotherapy. The pathology and biomarker reports help clarify which of these categories may be relevant, but they do not make the decision. Stage, tumour location, lung function, other medical conditions and your goals all matter.
A surgical report or imaging report may describe the size and location of the tumour and whether nearby structures are involved. That information helps the treating team judge whether an operation such as a lobectomy is technically possible and appropriate. A lung lobectomy removes one lobe of the lung; it is different from removing an entire lung. Whether that operation is suitable for you is a clinical judgement that depends on your individual situation.
If you are seeking care in China, ask the treating team what additional imaging or tests they would need before discussing local or systemic options. Do not send a partial file and expect a complete plan. A records-based opinion can identify what is missing and what questions to ask, but it does not replace an in-person assessment or establish hospital acceptance.
Questions to ask before you send your reports
Before sharing your diagnosis report with a hospital or coordination service in China, clarify a few practical points. These are not clinical decisions; they are about making sure the right information reaches the right people.
Ask your current hospital: Can I obtain the full pathology report, including the addendum or molecular section? Can I get the actual slides or blocks, or only a digital copy? Is there a treatment summary that lists prior therapies and responses?
Ask the receiving team: Which reports do you need first? Do you require the original slides or blocks, or is a scanned copy enough to start? Which biomarkers do you consider essential for this diagnosis? What additional tests would you recommend if the current reports are incomplete?
Ask about the review process: Who will review the pathology and biomarker reports? Will the case be discussed by more than one specialty? What is the expected next step after the review? These questions help you understand the scope of the opinion you are requesting.
What the reports cannot tell you, and what to confirm
A pathology or biomarker report cannot tell you whether you will respond to a treatment, how long you will live, or whether you should travel to China. It also cannot confirm that a particular hospital will accept your case or that a specific therapy is available. Those are separate questions that require direct confirmation from the treating team and the hospital.
What the reports can do is narrow the questions. They tell the treating team which subtype and molecular features are present, which tests were performed and which were not, and whether the sample was adequate. That is enough to ask focused questions: which markers matter for this diagnosis, whether the existing tissue can support further testing, and what additional imaging or sampling the team would need before discussing local or systemic options.
If you are considering care in China, start with a brief summary of your diagnosis and your main question. An initial enquiry is free and does not require buying a proxy consultation. The team can check what information is available, identify what is missing, and suggest a relevant next step. Hospital suitability and treatment decisions remain with the treating clinicians.
Do not delay urgent local care while waiting for an overseas reply. If your symptoms worsen, seek local medical attention first. For non-urgent planning, gather your reports, write down your questions, and ask the receiving team what they need to give you a useful answer.
A practical way to organise this is to keep three lists. One list holds the documents you already have: pathology report, biomarker report, imaging, treatment summary. A second list holds the questions you want answered: which biomarkers were tested, whether the sample was adequate, and what the team would need to assess local versus systemic options. A third list holds the practical items: how to send records, who reviews them, and what the next step is. Keeping these separate stops a clinical question from being buried under logistics, and it gives the receiving team a clear starting point.
When you contact a hospital or coordination service, lead with the diagnosis and the single most important question. A short, specific summary is easier to act on than a full archive sent without context. You can share more records after the first reply. The goal of that first exchange is not a treatment plan; it is to confirm what the team can review, what is missing, and what the realistic next step is.
Finally, treat the reports as a starting point for a conversation, not a verdict. They describe the cancer as it appeared in the sample. Your treating team combines that with your stage, general health, prior treatment and your own priorities. Ask them how each report changes their thinking, and ask what would make them reconsider. Those questions are more useful than trying to interpret the reports alone.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.